AlphaStocks
3.4
Weak

Astrana Health, Inc. (ASTH)

Health Care / Health Care Facilities

S&P SmallCap 600

$24.51

Scores poorly across most models. Proceed with caution.

Weak

Score based on 5 of 5 models — high confidence

#954out of 1127 in Health Care

Is Astrana Health, Inc. a Good Investment in 2026?

Astrana Health, Inc. (ASTH) scores 3.4 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Greenblatt Magic Formula model rates Astrana Health, Inc. as Strong (Top 25% (rank 20%)). However, the Lynch model rates it Caution — PEG 3.5 · Stalwart. Astrana Health, Inc. currently trades above its estimated fair value of $14, suggesting limited upside at current prices. Astrana Health, Inc. ranks #954 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E44.6ROE3.5Market Cap1BDiv Yield0.7

Estimated Fair Value

$14.1673% above

Trading above estimated fair value. P/e of 45x implies high growth expectations. eps growth of -47% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

72% above fair value

Lynch

Caution

PEG 3.5 · Stalwart

Greenblatt

Strong

Top 25% (rank 20%)

Frequently Asked Questions

Is Astrana Health, Inc. (ASTH) a good investment?
Based on AlphaStocks' composite analysis, Astrana Health, Inc. (ASTH) scores 3.4 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading above estimated fair value. P/e of 45x implies high growth expectations. eps growth of -47% may not justify the premium.
What is Astrana Health, Inc.'s Piotroski F-Score?
Astrana Health, Inc.'s Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ASTH overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $14, ASTH appears overvalued. The stock currently trades 73% above its estimated fair value. Trading above estimated fair value. P/e of 45x implies high growth expectations. eps growth of -47% may not justify the premium.
How does ASTH compare to other Health Care stocks?
Astrana Health, Inc. ranks #954 out of 1127 stocks in the Health Care sector, placing it in the top 85% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about ASTH?
AlphaStocks evaluates ASTH using five proven investment models. Piotroski: Neutral; Buffett: Neutral; Graham: Caution; Lynch: Caution; Greenblatt Magic Formula: Strong. These models are combined into a single composite score of 3.4/10.

Similar Stocks

PARRFTIAZN

Compare ASTH with

ASTH vs PARRASTH vs FTIASTH vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer